Increases in β-amyloid protein in the hippocampus caused by diabetic metabolic disorder are blocked by minocycline through inhibition of NF-κB pathway activation

Pharmacological Reports

Volumn 63, Issue 2, 2011, Pages 381-391

  Cai, Zhiyou ^a   Zhao, Yu ^b   Yao, Shengtao ^c   Zhao, Bin ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c ZUNYI MEDICAL UNIVERSITY   (China)

Author keywords

Diabetes mellitus; Minocycline; NF B; amyloid protein

Indexed keywords

AMYLOID BETA PROTEIN; BETA SECRETASE 1; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; MINOCYCLINE; STREPTOZOCIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INJURY; BRAIN LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; HIPPOCAMPUS; LEARNING; MALE; MEMORY; METABOLIC DISORDER; NEUROPROTECTION; NONHUMAN; PROPHYLAXIS; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 79955941855     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70504-7     Document Type: Article

References (74)

1. Abdel-Salam OM: Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets, 2008, 7, 321-342.
2. Agostini M, Di Marco B, Nocentini G, Delfino DV: Oxidative stress and apoptosis in immune diseases. Int J Immunopathol Pharmacol, 2002, 15, 157-164. (Pubitemid 35285193)
3. Alzheimer research forum live discussion: is Alzheimer's a type 3 diabetes? J Alzheimers Dis, 2006, 9, 349-353.
4. Akama KT, Albanese C, Pestell RG, Van Eldik LJ: Amyloid β-peptide stimulates nitric oxide production in astrocytes through an NFκB-dependent mechanism. Proc Natl Acad Sci USA, 1998, 95, 5795-5800. (Pubitemid 28224176)
5. Akama KT, Van Eldik LJ: β-Amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1β and tumor necrosis factor-α (TNFα)-dependent, and involves a TNFα receptor-associated factor- and NFκB-inducing kinase-dependent signaling mechanism. J Biol Chem, 2000, 275, 7918-7924. (Pubitemid 30159700)
6. Biessels GJ, Kappelle LJ: Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem Soc Trans, 2005, 33, 1041-1044.
7. Blum D, Chtarto A, Tenenbaum L, Brotchi J, Levivier M: Clinical potential of minocycline for neurodegenerative disorders. Neurobiol Dis, 2004, 17, 359-366. (Pubitemid 39574870)
8. Bours V, Bonizzi G, Bentires-Alj M, Bureau F, Piette J, Lekeux P, Merville M: NF-κB activation in response to toxical and therapeutical agents: role in inflammation and cancer treatment. Toxicology, 2000, 153, 27-38.
9. Cai F, Li C, Wu J, Min Q, Ouyang C, Zheng M, Ma S et al.: Modulation of the oxidative stress and nuclear factor κB activation by theaflavin 3,3′-gallate in the rats exposed to cerebral ischemia-reperfusion. Folia Biol (Praha), 2007, 53, 164-172. (Pubitemid 47559232)
10. Cai Z, Lin S, Fan LW, Pang Y, Rhodes PG: Minocycline alleviates hypoxic-ischemic injury to developing oligodendrocytes in the neonatal rat brain. Neuroscience, 2006,137, 425-435. (Pubitemid 43031509)
11. Cai ZY, Yan Y, Chen R: Minocycline reduces astrocytic reactivation and neuroinflammation in the hippocampus of a vascular cognitive impairment rat model. Neurosci Bull, 2010,26, 28-36.
12. Cai ZY, Yan Y, Sun SQ, Zhang J, Huang LG, Yan N, Wu F, Li JY: Minocycline attenuates cognitive impairment and restrains oxidative stress in the hippocampus of rats with chronic cerebral hypoperfusion. Neurosci Bull, 2008, 24, 305-313.
13. 4 plus ascorbate. Mol Cell Biochem, 2008, 311, 167-177.
14. Chavez M, Seeley RJ, Havel PJ, Friedman MI, Matson CA, Woods SC, Schwartz MW: Effect of a high-fat diet on food intake and hypothalamic neuropeptide gene expression in streptozotocin diabetes. J Clin Invest, 1998,102, 340-346. (Pubitemid 28335193)
15. Choi Y, Kim HS, Shin KY, Kim EM, Kim M, Kim HS, Park CH et al.: Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. Neuropsychopharmacology, 2007, 32, 2393-2404. (Pubitemid 47587688)
16. Ckless K, van der Vliet A, Janssen-Heininger Y: Oxidative-nitrosative stress and post-translational protein modifications: implications to lung structure-function relations. Arginase modulates NF-κB activity via a nitric oxide-dependent mechanism. Am J Respir Cell Mol Biol, 2007, 36, 645-653. (Pubitemid 46871418)
17. Csiszar A, Labinskyy N, Podlutsky A, Kaminski PM, Wolin MS, Zhang C, Mukhopadhyay P et al.: Vasoprotective effects of resveratrol and SIRT1: attenuation of cigarette smoke-induced oxidative stress and proinflammatory phenotypic alterations. Am J Physiol Heart Circ Physiol, 2008, 294, 2721-2735.
18. de la Monte SM: Insulin resistance and Alzheimer's disease. BMB Rep, 2009, 42, 475-481.
19. de la Monte SM, Tong M, Lester-Coll N, Plater M Jr, Wands JR: Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J Alzheimers Dis, 2006, 10, 89-109. (Pubitemid 44401370)
20. Duyckaerts C, Delatour B, Potier MC: Classification and basic pathology of Alzheimer disease. Acta Neuropathol, 2009, 118, 5-36.
21. El Bekay R, Alvarez M, Monteseirín J, Alba G, Chacón P, Vega A, Martin-Nieto J et al.: Oxidative stress is a critical mediator of the angiotensin II signal in human neutrophils: involvement of mitogen-activated protein kinase, calcineurin, and the transcription factor NF-κB. Blood, 2003, 102, 662-671. (Pubitemid 36841990)
22. Gasparini L, Netzer WJ, Greengard P, Xu H: Does insulin dysfunction play a role in Alzheimer's disease? Trends Pharmacol Sci, 2002, 23, 288-293.
23. Giovannini MG, Scali C, Prosperi C, Bellucci A, Vannucchi MG, Rosi S, Pepeu G, Casamenti F: β-Amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiol Dis, 2002, 11, 257-274. (Pubitemid 36135690)
24. Gomez NN, Davicino RC, Biaggio VS, Bianco GA, Alvarez SM, Fischer P, Masnatta L: Overexpression of inducible nitric oxide synthase and cyclooxygenase-2 in rat zinc-deficient lung: Involvement of a NF-κB dependent pathway. Nitric Oxide, 2006, 14, 30-38.
25. Gorlach A, Bonello S: The cross-talk between NF-κB and HIF-1: further evidence for a significant liaison. Biochem J, 2008, 412, e17-19.
26. Grünblatt E, Koutsilieri E, Hoyer S, Riederer P: Gene expression alterations in brain areas of intracerebroventricular streptozotocin treated rat. J Alzheimers Dis, 2006, 9, 261-271. (Pubitemid 44253344)
27. Hampel H, Shen Y: Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease. Scand J Clin Lab Invest, 2009, 69, 8-12.
28. Hayakawa K, Mishima K, Nozako M, Hazekawa M, Mishima S, Fujioka M, Orito K et al.: Delayed treatment with minocycline ameliorates neurologic impairment through activated microglia expressing a high-mobility group box1-inhibiting mechanism. Stroke, 2008, 39, 951-958. (Pubitemid 351619558)
29. 276 phosphorylation and enhanceosome formation is mediated by an ROS-dependent PKAc pathway. Cell Signal, 2007, 19, 1419-1433.
30. Joshi-Barve S, Barve SS, Butt W, Klein J, McClain CJ: Inhibition of proteasome function leads to NF-κB-independent IL-8 expression in human hepatocytes. Hepatology, 2003, 38, 1178-1187. (Pubitemid 37314826)
31. Kim HS, Suh YH: Minocycline and neurodegenerative diseases. Behav Brain Res, 2009, 196, 168-179.
32. Kim SS, Kong PJ, Kim BS, Sheen DH, Nam SY, Chun W: Inhibitory action of minocycline on lipopoly-saccharide-induced release of nitric oxide and prostaglandin E2 in BV2 microglial cells. Arch Pharm Res, 2004, 27, 314-318.
33. Kobayashi D, Zeller M, Cole T, Buttini M, McConlogue L, Sinha S, Freedman S et al.: BACE1 gene deletion: impact on behavioral function in a model of Alzheimer's disease. Neurobiol Aging, 2008, 29, 861-873. (Pubitemid 351601901)
34. Kroner Z: The relationship between Alzheimer's disease and diabetes: Type 3 diabetes? Altern Med Rev, 2009, 14, 373-379.
35. Kuang X, Scofield VL, Yan M, Stoica G, Liu N, Wong PK: Attenuation of oxidative stress, inflammation and apoptosis by minocycline prevents retrovirus-induced neurodegeneration in mice. Brain Res, 2009, 1286, 174-184.
36. Lee SY, Lee JW, Lee H, Yoo HS, Yun YP, Oh KW, Ha TY, Hong JT: Inhibitory effect of green tea extract on β-amyloid-induced PC12 cell death by inhibition of the activation of NF-κB and ERK/p38 MAP kinase pathway through antioxidant mechanisms. Brain Res Mol Brain Res, 2005, 140, 45-54. (Pubitemid 41446146)
37. 1- antichymotrypsin in human astrocytoma cells by activation of nuclear factor-κB. J Neurochem, 1996, 67, 2039-2044.
38. Liu Z, Fan Y, Won SJ, Neumann M, Hu D, Zhou L, Weinstein PR, Liu J: Chronic treatment with minocycline preserves adult new neurons and reduces functional impairment after focal cerebral ischemia. Stroke, 2007, 38, 146-152. (Pubitemid 46035620)
39. López-Franco O, Hernández-Vargas P, Ortiz-Muñoz G, Sanjuán G, Suzuki Y, Ortega L, Blanco J et al.: Parthenolide modulates the NF-κB-mediated inflammatory responses in experimental atherosclerosis. Arterioscler Thromb Vasc Biol, 2006, 26, 1864-1870. (Pubitemid 44305342)
40. Lu J, Wu DM, Zheng YL, Sun DX, Hu B, Shan Q, Zhang ZF, Fan SH: Trace amounts of copper exacerbate beta amyloid-induced neurotoxicity in the cholesterolfed mice through TNF-mediated inflammatory pathway. Brain Behav Immun, 2009, 23, 193-203.
41. Marcello E, Epis R, Di Luca M: Amyloid flirting with synaptic failure: towards a comprehensive view of Alzheimer's disease pathogenesis. Eur J Pharmacol, 2008, 585, 109-118.
42. Matroule JY, Volanti C, Piette J: NF-κB in photodynamic therapy: discrepancies of a master regulator. Photochem Photobiol, 2006, 82, 1241-1246. (Pubitemid 44702003)
43. Milionis HJ, Florentin M, Giannopoulos S: Metabolic syndrome and Alzheimer's disease: a link to a vascular hypothesis? CNS Spectr, 2008, 13, 606-613.
44. Mogensen TH, Melchjorsen J, Höllsberg P, Paludan SR: Activation of NF-κB in virus-infected macrophages is dependent on mitochondrial oxidative stress and intracellular calcium: downstream involvement of the kinases TGF-β-activated kinase 1, mitogen-activated kinase/extracellular signal-regulated kinase kinase 1, and IκB kinase. J Immunol, 2003, 170, 6224-6233. (Pubitemid 36682607)
45. Neumann KF, Rojo L, Navarrete LP, Farías G, Reyes P, Maccioni RB: Insulin resistance and Alzheimer's disease: molecular links & clinical implications. Curr Alzheimer Res, 2008, 5, 438-447.
46. Nilsson OG, Shapiro ML, Gage FH, Olton DS, Björklund A: Spatial learning and memory following fimbria-fornix transection and grafting of fetal septal neurons to the hippocampus. Exp Brain Res, 1987, 67, 195-215. (Pubitemid 17100469)
47. Paine AJ, Andreakos E: Activation of signalling pathways during hepatocyte isolation: relevance to toxicology in vitro. Toxicol In Vitro, 2004, 18, 187-193. (Pubitemid 38125198)
48. Pasquier F, Boulogne A, Leys D, Fontaine P: Diabetes mellitus and dementia. Diabetes Metab, 2006, 32, 403-414. (Pubitemid 44841847)
49. Plastino M, Fava A, Pirritano D, Cotronei P, Sacco N, Sperlì T, Spanò A et al.: Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2. J Neurol Sci, 2010, 288, 112-116.
50. Poli MA, Rivera VR, Neal D: Sensitive and specific colorimetric ELISAs for Staphylococcus aureus enterotoxins A and B in urine and buffer. Toxicon, 2002, 40, 1723-1726. (Pubitemid 35379727)
51. Prasad PV, Chaube SK, Shrivastav TG, Kumari GL: Development of colorimetric enzyme-linked immunosorbent assay for human chorionic gonadotropin. J Immunoassay Immunochem, 2006, 27, 15-30. (Pubitemid 43087624)
52. Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett JG, Gadbois TM, Reaven GM: A new rat model of type 2 diabetes: the fat-fed, streptozotocin- treated rat. Metabolism, 2000, 49, 1390-1394.
53. Reid PC, Urano Y, Kodama T, Hamakubo T: Alzheimer's disease: cholesterol, membrane rafts, isoprenoids and statins. J Cell Mol Med, 2007, 11, 383-392. (Pubitemid 47153452)
54. Rodrigues GB, Passos GF, Di Giunta G, Figueiredo CP, Rodrigues EB, Grumman A Jr, Medeiros R, Calixto JB: Preventive and therapeutic anti-inflammatory effects of systemic and topical thalidomide on endotoxin-induced uveitis in rats. Exp Eye Res, 2007, 84, 553-560. (Pubitemid 46210059)
55. Roriz-Filho JS, Sá-Roriz TM, Rosset I, Camozzato AL, Santos AC, Chaves ML, Moriguti JC, Roriz-Cruz M: (Pre)diabetes, brain aging, and cognition. Biochim Biophys Acta, 2009, 1792, 432-443.
56. Sahnoun Z, Jamoussi K, Zeghal KM: Free radicals and antioxidants: physiology, human pathology and therapeutic aspects (part II) (French). Therapie, 1998, 53, 315-339.
57. Sanz C, Andrieu S, Sinclair A, Hanaire H, Vellas B; REAL: FR Study Group. Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease. Neurology, 2009, 73, 1359-1366.
58. Schaue D, Jahns J, Hildebrandt G, Trott KR: Radiation treatment of acute inflammation in mice. Int J Radiat Biol, 2005, 81, 657-667. (Pubitemid 43169757)
59. Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P: Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res, 2005, 52, 313-320. (Pubitemid 41175991)
60. Sriram K, Miller DB, O'Callaghan JP: Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-α. J Neurochem, 2006, 96, 706-718.
61. Stolp HB, Ek CJ, Johansson PA, Dziegielewska KM, Potter AM, Habgood MD, Saunders NR: Effect of minocycline on inflammation-induced damage to the bloodbrain barrier and white matter during development. Eur J Neurosci, 2007, 26, 3465-3474. (Pubitemid 350243544)
62. Summers WK: Alzheimer's disease, oxidative injury, and cytokines. J Alzheimers Dis, 2004, 6, 651-657; discussion 673-681.
63. Tahara A, Matsuyama-Yokono A, Nakano R, Someya Y, Hayakawa M, Shibasaki M: Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors. Pharmacol Rep, 2009, 61, 899-908.
64. Tees RC, Buhrmann K, Hanley J: The effect of early experience on water maze spatial learning and memory in rats. Dev Psychobiol, 1990, 23, 427-439. (Pubitemid 20368143)
65. Thomas M, Ashizawa T, Jankovic J: Minocycline in Huntington's disease: a pilot study. Mov Disord, 2004, 19, 692-695. (Pubitemid 39173025)
66. Thomas M, Le WD: Minocycline: neuroprotective mechanisms in Parkinson's disease. Curr Pharm Des, 2004, 10, 679-686.
67. Tomás-Camardiel M, Rite I, Herrera AJ, de Pablos RM, Cano J, Machado A, Venero JL: Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system. Neurobiol Dis, 2004, 16, 190-201. (Pubitemid 38569810)
68. Watała C, Kaźmierczak P, Dobaczewski M, Przygodzki T, Bartuś M, Łomnicka M, Słomińska EM et al.: Anti-diabetic effects of 1-methylnicotinamide (MNA) in streptozocin-induced diabetes in rats. Pharmacol Rep, 2009, 61, 86-98.
69. Yang Y, Yang Y, Xu Y, Lick SD, Awasthi YC, Boor PJ: Endothelial glutathione-S-transferase A4-4 protects against oxidative stress and modulates iNOS expression through NF-κB translocation. Toxicol Appl Pharmacol, 2008, 230, 187-196.
70. Yenari MA, Xu L, Tang XN, Qiao Y, Giffard RG: Microglia potentiate damage to blood-brain barrier constituents: improvement by minocycline in vivo and in vitro. Stroke, 2006, 37, 1087-1093.
71. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM: The promise of minocycline in neurology. Lancet Neurol, 2004, 3, 744-751. (Pubitemid 39535260)
72. Zhang N, Ahsan MH, Zhu L, Sambucetti LC, Purchio AF, West DB: NF-κB and not the MAPK signaling pathway regulates GADD45β expression during acute inflammation. J Biol Chem, 2005, 280, 21400-21408. (Pubitemid 40805704)
73. Zhiyou C, Yong Y, Shanquan S, Jun Z, Liangguo H, Ling Y, Jieying L: Upregulation of BACE1 and β-amyloid protein mediated by chronic cerebral hypoperfusion contributes to cognitive impairment and pathogenesis of Alzheimer's disease. Neurochem Res, 2009, 34, 1226-1235.
74. Zingg JM, Ricciarelli R, Azzi A: Scavenger receptors and modified lipoproteins: fatal attractions? IUBMB Life, 2000, 49, 397-403.